Skip to main content
Premium Trial:

Request an Annual Quote

LexaGene Announces C$5M Bought Deal Financing

NEW YORK (GenomeWeb) – LexaGene announced today that it has entered an agreement with a group of underwriters led by Canaccord Genuity to purchase up to 5 million units of stock at a price of $1.00 per unit, for gross proceeds of C$5.0 million ($3.7 million).

Each unit will consist of one common share of the company and one half of one common share purchase warrant, with each share entitling the holder to acquire one share at a price of C$1.30 until June 22, 2021.

LexaGene has also granted underwriters a 30-day option to purchase up to an additional 750,000 shares at a price of $1.00 per unit, exercisable at any time. The offering is expected to close on July 11, 2018.

LexaGene, which trades over the counter and on the Toronto Stock Exchange, plans to use the net proceeds to advance commercialization of its microfluidic technology and for general corporate purposes. The company is currently targeting the food safety and veterinary diagnostic markets with its technology.

Earlier this month, LexaGene announced that it has partnered with Texas A&M to test canine urine samples on the firm's LX6 prototype pathogen detection instrument. LexaGene has also partnered with Stanford University to use the university's cancer sequencing technology in combination with the firm's microfluidic instrument.

The Scan

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Targets Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.